Beam Therapeutics BEAM Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's deferred revenue?
- Beam Therapeutics (BEAM) reported deferred revenue of $304K in Q1 2026.
- How has Beam Therapeutics's deferred revenue changed year-over-year?
- Beam Therapeutics's deferred revenue decreased by 99.6% year-over-year, from $85.2M to $304K.
- What is the long-term trend for Beam Therapeutics's deferred revenue?
- Over 5 years (2020 to 2025), Beam Therapeutics's deferred revenue has grown at a 208.1% compound annual growth rate (CAGR), from $24K to $6.66M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.